Expanded PBS listing for empagliflozin

2 minute read


The SGLT2 inhibitor is now subsidised for people at increased cardiovascular risk without the need for an unmet glycaemic target.


This content is for AHPRA registered professionals only.
Join Now

End of content

No more pages to load

Log In Register ×